Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07384975 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Navigator Medicines.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 10
- Study locations
NCT07384975: Recruiting Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Navigator Medicines.
NCT07384975 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Navigator Medicines. The registered enrollment target is 150 participants, below the 168-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (11% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07384975, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Navigator Medicines.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 10
- Study locations
Study Summary
The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study). Participants will: * Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.
Primary Outcome
HiSCR75 is defined as at least a 75% reduction in total abscess and inflammatory nodule count (AN count) with no increase in abscess count and no increase in draining tunnel count relative to baseline.
Conditions Studied
Interventions
- DRUG NAV-240
- DRUG Placebo to match NAV-240
Study Locations (10)
Florida
- Accel Research Sites Network - Maitland
- Floridian Research Institute - Miami
- Cordova Research Institute - Miami
- Tory Sullivan MD PA - Dermatology - North Miami Beach
- MplusM - D&H Tamarac Research Center - Tamarac
- ForCare Clinical Research - Tampa
Arizona
- Medical Dermatology Specialist - Phoenix
Kentucky
- Kentucky Advanced Medical Research LLC - Murray
New Hampshire
- ActivMed Practices & Research, LLC - Portsmouth
New York
- Equity Medical, LLC - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT07384975 shows while recruiting
NCT07384975 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 168-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 2 interventions - of which NAV-240 is the first listed.
NCT07384975 lists 10 locations in 5 states (Florida, Arizona, Kentucky).
Frequently Asked Questions
What is clinical trial NCT07384975 about?
NCT07384975 is a clinical study titled "A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa". The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 1...
What is the current status of trial NCT07384975?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-01-05. Estimated completion is 2027-10.
What conditions does trial NCT07384975 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07384975?
The interventions under investigation include: NAV-240 (DRUG), Placebo to match NAV-240 (DRUG).
Who is sponsoring clinical trial NCT07384975?
This trial is sponsored by Navigator Medicines, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07384975 being conducted?
This trial has 10 study locations across Arizona, Florida, Kentucky, New Hampshire, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07384975's enrollment target sits among peer trials
150 6th of 12 higher than 7 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI